Analysts expect that Travere Therapeutics, Inc. (NASDAQ:TVTX) will report earnings per share of ($0.73) for the current quarter, according to Zacks. Four analysts have made estimates for Travere Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.68) and the lowest estimate coming in at ($0.79). Travere Therapeutics posted earnings per share of ($0.58) in the same quarter last year, which would indicate a negative year-over-year growth rate of 25.9%. The business is scheduled to announce its next earnings results on Thursday, July 29th.
On average, analysts expect that Travere Therapeutics will report full-year earnings of ($3.18) per share for the current year, with EPS estimates ranging from ($3.45) to ($2.87). For the next financial year, analysts expect that the firm will post earnings of ($3.14) per share, with EPS estimates ranging from ($3.64) to ($2.00). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Travere Therapeutics.
Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, May 6th. The company reported ($0.96) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.40). Travere Therapeutics had a negative net margin of 113.21% and a negative return on equity of 75.08%. The business had revenue of $47.41 million for the quarter, compared to analyst estimates of $49.99 million.
In related news, CEO Eric M. Dube sold 9,562 shares of the business’s stock in a transaction dated Wednesday, June 2nd. The shares were sold at an average price of $14.62, for a total transaction of $139,796.44. 4.31% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Penserra Capital Management LLC bought a new position in Travere Therapeutics in the 4th quarter worth about $31,000. Altshuler Shaham Ltd bought a new position in Travere Therapeutics in the 1st quarter worth about $36,000. Exane Derivatives bought a new position in Travere Therapeutics in the 1st quarter worth about $43,000. Pacer Advisors Inc. grew its position in Travere Therapeutics by 48.0% in the 1st quarter. Pacer Advisors Inc. now owns 2,293 shares of the company’s stock worth $57,000 after purchasing an additional 744 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new position in Travere Therapeutics in the 4th quarter worth about $98,000.
TVTX stock traded down $0.34 during trading on Friday, reaching $13.40. The stock had a trading volume of 10,426 shares, compared to its average volume of 703,376. Travere Therapeutics has a 1-year low of $13.24 and a 1-year high of $33.09. The company has a debt-to-equity ratio of 0.60, a current ratio of 6.65 and a quick ratio of 6.56. The firm has a market capitalization of $810.16 million, a P/E ratio of -3.16 and a beta of 0.67. The company has a fifty day moving average of $15.42.
About Travere Therapeutics
Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.
See Also: dividend yield calculator
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.